ABSTRACT
Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, improved outcomes in a previous randomized controlled trial of hospitalized adults with COVID-19, in combination with remdesivir.
Methods In this phase 3, global, double-blind, randomized, placebo-controlled trial, 1525 hospitalized adults with COVID-19 receiving standard of care (SOC) were randomly assigned (1:1) to once-daily baricitinib 4-mg (N=764) or placebo (N=761) for up to 14 days. SOC included systemic corticosteroids in ∼79% of participants (dexamethasone ∼90%). The primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28. A key secondary endpoint was all-cause mortality by day 28.
Results Overall, 27.8% of participants receiving baricitinib vs 30.5% receiving placebo progressed (primary endpoint, odds ratio 0.85, 95% CI 0.67-1.08; p=0.18). The 28-day all-cause mortality was 8.1% for baricitinib and 13.1% for placebo, corresponding to a 38.2% reduction in mortality (hazard ratio [HR] 0.57, 95% CI 0.41-0.78; nominal p=0.002); 1 additional death was prevented per 20 baricitinib-treated participants. Reduction in mortality was seen for all pre-specified subgroups of baseline severity (most pronounced for participants on high-flow oxygen/non-invasive ventilation at baseline [17.5%, baricitinib vs 29.4%, placebo; HR 0.52, 95% CI 0.33-0.80; nominal p=0.007]). The frequency of adverse events, serious adverse events, serious infections, and venous thromboembolic events was similar between groups.
Conclusions While reduction of disease progression did not achieve statistical significance, treatment with baricitinib in addition to SOC (predominantly dexamethasone) significantly reduced mortality with a similar safety profile between groups of hospitalized COVID-19 participants.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form and declare: Vincent C. Marconi received research grants from CDC, Gilead Sciences, NIH, VA, and ViiV, received honoraria from Eli Lilly and Company, served as an advisory board member for Eli Lilly and Company and Novartis and participated as a study section chair for the NIH. Athimalaipet V. Ramanan received research grants from Eli Lilly and Company, served as a speaker and/or consultant for AbbVie, Eli Lilly and Company, Novartis, Pfizer, Roche, Sobi and UCB. Stephanie de Bono, Cynthia E. Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B. Piruzeli, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, and David H. Adams are employees and shareholders of Eli Lilly and Company. Jason D. Goldman received research support from Eli Lilly and Company, Regeneron Pharmaceuticals, and Gilead Sciences, grants from Eurofins Viracor, the Biomedical Advanced Research and Development Authority (administered by Merck), speaker fees from Gilead Sciences, Mylan Pharmaceuticals and advisory board fees from Gilead Sciences. Rita de Cassia Pellegrini has no conflicts to disclose. Jorge Alatorre-Alexander served as a speaker and scientific advisor for Astra Zeneca, Boehringer Ingelheim, BMS, Eli Lilly and Company, Foundation Medicine, Novartis, MSD, Roche and Takeda. Vicente Estrada received a research grant from Eli Lilly and Company. Mousumi Som received research grants from Eli Lilly and Company, NIAID, Novartis and served as a board member for NBOME, Osteopathic Founders Foundation and COGMED. E. Wesley Ely received research grants from CDC, NIH and VA, and served as an unpaid consultant for Eli Lilly and Company.
Clinical Trial
NCT04421027
Funding Statement
This study was funded by Eli Lilly and Company, under license from Incyte Corporation. All authors received manuscript preparation support from Eli Lilly and Company. Stephanie de Bono, Cynthia E. Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B. Piruzeli, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, and David H. Adams are Employees and stockholders of Eli Lilly and Company. Jason D. Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, and Mousumi Som or their institutions were paid as study investigators. Athimalaipet V. Ramanan is a paid advisor. Vincent C. Marconi and E. Wesley Ely received no funding for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All sites received approval from the authorized institutional review board (See 'COV-BARRIER_IRB_Report.docx'). All patients (or legally authorized representatives) provided informed consent. An independent, external data monitoring committee oversaw the study and evaluated unblinded interim data for efficacy, futility and safety analyses. An independent, blinded, clinical event committee adjudicated potential VTEs and deaths.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* A complete list of members of the COV-BARRIER Study Group is provided in the Supplementary Appendix.
Data Availability
Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after the trial is completed, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.
